Abstract
To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection. Brain tumor patients undergoing neurosurgery with ≥1 seizure within the preceding month prior to surgery were enrolled to receive intravenous levetiracetam for a minimum of 48 h, transitioned to oral levetiracetam at the same dose, and followed for 1-month after discharge. Patients were assessed daily in the hospital, provided with a seizure diary, and supplied with 30 days of levetiracetam upon discharge. Study patients were telephoned weekly to assess their cognitive status and seizure frequency. Of the 17 patients enrolled, the baseline seizure types were tonic clonic, partial, and complex partial with secondary generalization. The most common type of tumor was glioblastoma multiforme. Levetiracetam was well tolerated with no medication discontinuation during the study period. Adverse effects reported were somnolence, nausea/vomiting, headache, and insomnia. Eleven patients were evaluable for TICS scores (64.7%) with an average score of 33.3. Two patients were deemed to be cognitively impaired (18.2%). Eleven of twelve patients (91.7%) that completed the study period achieved a ≥50% reduction in their number of seizures. A total of 92 drug interactions were avoided (P = 0.0016) with dexamethasone, acetaminophen, and fentanyl being the most common. Levetiracetam monotherapy was found to be safe and tolerable in this patient population. Nearly all patients achieved a ≥50% reduction in seizure frequency post-op with levetiracetam monotherapy. Levetiracetam also has the potential for less drug interactions compared to phenytoin in these patients.
Similar content being viewed by others
References
Central Brain Tumor Registry of the United States (2007–08) CBTRUS, Chicago
Posner JB (1992) Management of brain metastases. Rev Neurol (Paris) 148:477–487
Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31
Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T (2001) Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-Oncology 3(3):152–158
Villemure JG, de Tribolet N (1996) Epilepsy in patients with central nervous system tumors. Curr Opin Neurol 9(6):424–428
Wen P (1997) The diagnosis and management of patients with brain tumors. In: Loeffler JS, Black PM (eds) Cancer of the nervous system. Blackwell Scientific, Boston, pp 106–127
Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52:717–724
Mamon HJ, Wen PY, Burns AC, Loeffler JS (1999) Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 40:341–344
Mahaley MS, Dudka L (1981) The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg Neurol 16:399–401
Hagen NA, Cirrincione C, Thaler HT et al (1990) The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 40:158–160
Hung S, Hilsenbeck S, Feun L (1999) Seizure prophylaxis with phenytoin in patients with brain metastases. Proc Am Soc Clin Oncol 10:A1151
Moots PL, Maciunas RJ, Eisert DR et al (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52:717–724
Glantz MJ, Cole BF, Friedberg MH et al (1996) A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46:985–991
Forsyth PA, Weaver S, Fulton D et al (2003) Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 30(2):89–90
VanLandingham KE, Radtke RA (2002) Use of levetiracetam in patients with brain tumors and intractable partial epilepsy. Epilepsia 43(7):202
Siddiqui F, Wen P, Dworetzky B, Cabello D, Broomfield EB (2002) Use of levetiracetam in patients with brain tumors. Epilepsia 43(7):297
Penovich PE, Dickens DL, Gates JR et al (2004) Treating seizures due to brain neoplasms: rational new choices. Epilepsia 45(7):311
Larson SE, Sirven JI, Drazkowski JF, Zimmerman RS (2004) Efficacy and tolerability of levetiracetam in patients with brain tumors and seizures. Epilepsia 45(7):124
Stevens GHJ, Vogelbaum MA, Suh JH, Peereboom DM, Barnett GH (2005) Levetiracetam use in brain tumor patients. Neurology 64(1):A47–A48
Brandt J, Spencer M, Folstein M (1988) The telephone interview for cognitive status. Neuropsychiatr, Neuropsychol Behav Neurol 1(2):111–117
Ferrucci L, Del Lungo I, Guralnik JM et al (1998) Is the telephone interview for cognitive status a valid alternative in persons who cannot be evaluated by the mini mental state examination? Aging 10(4):332–338
Naidech AM, Kreiter KT, Janjua N et al (2005) Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 36:583–587
Sanchez CE, Ogilvy CS, Carter BS (2007) Outcomes studies in cerebrovascular neurosurgery. Neurosurg Focus 22(3):1–21
Valeriano JP, Lane CL (2005) Clinical experience with levetiracetam monotherapy in the treatment of epilepsy. Epilepsia 46(8):191
Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78(1):99–102
Newton HB, Dalton J, Goldlust S, Pearl D (2007) Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol 84(3):293–296
Rüegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P (2008) Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 12:477–480
Chang EF, Potts MB, Keles GE et al (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108:227–235
Milligan TA, Hurwitz S, Bromfield EB (2008) Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 71:665–669
Lim DA, Tarapore P, Chang E et al (2009) Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol 93(3):349–354
Acknowledgments
This research study was funded through a Young Investigator Research Grant provided by UCB Pharma.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Usery, J.B., Michael, L.M., Sills, A.K. et al. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol 99, 251–260 (2010). https://doi.org/10.1007/s11060-010-0126-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-010-0126-8